Magistral drugs in hospitalized newborns and children  by Pereira, Agueda Cabral de Souza et al.
Rev Paul Pediatr. 2016;34(4):403--407
REVISTA  PAULISTA
DE PEDIATRIA
www.rpped.com.br
ORIGINAL ARTICLE
Magistral  drugs  in  hospitalized  newborns  and children
Agueda Cabral de Souza Pereira, Elaine Silva Miranda,
Selma Rodrigues de Castilho, Débora Omena Futuro,
Lenise Arneiro Teixeira, Geraldo Renato de Paula ∗
Universidade  Federal  Fluminense  (UFF),  Niterói,  RJ,  Brazil
Received  4  November  2015;  accepted  22  February  2016
Available  online  26  July  2016
KEYWORDS
Medication  use;
Pediatric
medications;
Fractionated  drugs;
Unlicensed  drugs
Abstract
Objective:  Study  the  use  of  magistral  oral  solutions  and  suspensions  in  infants  and  children  at
a university  hospital.
Methods:  This  is  a  descriptive  study  based  on  the  analysis  of  the  assessed  hospital’s  magistral
drug request  forms  regarding  the  patients  in  the  neonatal  ICU,  Obstetrics,  Pediatrics  and  Pedi-
atric Emergency  from  January  2012  to  December  2013.  The  frequency  of  drug  requests  and
dispensation  was  evaluated  and  the  consumption  of  each  active  ingredient  of  the  preparations
was expressed  as  number  of  ‘‘infant  deﬁned  daily  dose’’  (iDDD)  and  of  iDDD/100  bed-days.
Results:  A  total  of  657  forms  were  analyzed--a  monthly  average  of  27  pediatric  preparations.
The neonatal  ICU  accounted  for  69.6%  of  these  requests.  Twenty-one  drug  items  were  used,  of
which the  most  common  were  folinic  acid  (88  requests),  sulfadiazine  (85)  and  captopril  (73).
The consumption  of  the  active  principle  in  these  preparations  varied  in  number  of  iDDD,  from
7.5 (hydralazine)  to  16,520.0  (folic  acid),  and  in  number  of  iDDD/100  bed-days  in  the  neonatal
ICU, from  0.1  (zinc  sulfate)  to  146.1  (folic  acid).
Conclusions:  The  constant  consumption  of  magistral  oral  solutions  and  suspensions  by  newborns
and children  of  the  assessed  hospital  indicates  the  need  for  such  preparations  as  a  pediatric
therapeutic  alternative  in  this  hospital.
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Medicamentos  magistrais  em  recém-nascidos  e  crianc¸as hospitalizados
Resumo
Objetivo:  Estudar  o  uso  de  soluc¸ões  e  suspensões  orais  magistrais  em  recém-nascidos  e  crianc¸as
de um  hospital  universitário.
Métodos:  Foi  feito  um  estudo  descritivo  a  partir  da  análise  dos  formulários  de  solicitac¸ão  de
manipulac¸ão do  hospital  estudado  referentes  aos  pacientes  da  UTI-neonatal,  obstetrícia,  pedi-
atria e  emergência  pediátrica  de  janeiro  de  2012  a  dezembro  de  2013.  As  frequências  das
solicitac¸ões e  dispensac¸ões  desses  medicamentos  foram  avaliadas  e  o  consumo  de  cada  princí-
pio ativo  das  preparac¸ões  foram  expressos  sob  a  forma  de  número  de  infant  deﬁned  daily  dose
(iDDD) e  de  iDDD/100  leitos-dia.
Resultados:  Foram  analisados  657  formulários--média  mensal  de  27  preparac¸ões  pediátricas.  A
UTI-neonatal  foi  responsável  por  69,6%  dessas  solicitac¸ões.  Foram  usados  21  itens  de  medica-
mentos,  destacou-se  o  uso  de  ácido  folínico  (88  solicitac¸ões),  sulfadiazina  (85)  e  captopril  (73).
O consumo  de  princípio-ativo  nessas  preparac¸ões  variou,  em  número  de  iDDD,  de  7,5  (hidralaz-
ina) a  16.520  (ácido  fólico)  e  em  número  de  iDDD/100  leitos-dia  da  UTI-neonatal,  de  0,1  (sulfato
de zinco)  a  146,1  (ácido  fólico).
Conclusões:  O  consumo  constante  das  soluc¸ões  e  suspensões  orais  magistrais  pelos  recém-
nascidos  e  crianc¸as  do  hospital  estudado  indica  a  necessidade  dessas  preparac¸ões  como  opc¸ão
terapêutica pediátrica  nesse  hospital.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um
artigo Open  Access  sob  uma  licenc¸a  CC  BY  (http://creativecommons.org/licenses/by/4.0/).
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ewborns  and  children  go  through  physiological  changes
hroughout  their  development,  which  interfere  with  the
harmacokinetics  and,  consequently,  the  safety  and  effec-
iveness  of  drug  treatment  in  the  pediatric  age  group.
herefore,  studies  are  needed  in  each  pediatric  subpopu-
ation  for  which  their  use  is  intended  aiming  at  safety  and
fﬁcacy  assessment  of  pediatric  drugs.1
However,  there  is  a  shortage  of  pediatric  drugs  in  the
harmaceutical  industry,  which  can  be  explained  by  eco-
omic,  ethical  and  technical  issues.  This  fact  makes  the
agistral  preparations  advantageous  options  for  obtain-
ng  medications  with  appropriate  pharmaceutical  form  for
ediatric  use,  as  they  allow  dose  ﬂexibility  and  easy  drug
dministration.1,2
In  Brazil,  the  preparation  of  compounded  drugs  must
omply  with  the  rules  of  the  Collegiate  Board  Resolution
RDC)  67/2007,  which  provides  for  Good  Compounding  Prac-
ices  of  Magistral  and  Compounded  Drugs  for  Human  Use
n  pharmacies.3 To  obtain  magistral  solutions  and  oral  sus-
ensions,  the  ﬁrst  choice  is  the  compounding  of  the  active
rinciple;  however,  these  can  also  be  obtained  by  diluting  a
iquid  formulation  (e.g.,  an  injectable  dilution),  provided
t  is  compatible  with  oral  administration,  by  pulverizing
ablets  or  removing  the  powder  from  the  capsule.4
This  study  aims  to  evaluate  the  use  of  magistral  oral  solu-
ions  and  suspensions  in  hospitalized  newborns  and  children.ethod
 descriptive,  retrospective  study  was  carried  out  based  on
he  analysis  of  request  forms  for  compounding  of  oral  liquid
t
oreparations  for  newborns  and  children  admitted  at  Hospital
niversitário  Antônio  Pedro  (HUAP)  of  Universidade  Federal
luminense  (UFF),  related  to  the  period  of  January  2012  to
ecember  2013.  This  is  a tertiary  and  quaternary  hospital,
as  287  beds  and  serves  the  population  of  the  Metropolitan
egion  II  of  the  State  of  Rio  de  Janeiro.
The  pediatric  oral  liquid  preparations  mentioned  in  this
tudy  were  prepared  at  the  pharmacy  of  the  UFF,  under  the
esponsibility  and  guidance  of  a  pharmacist,  with  formu-
ations  being  based  on  scientiﬁc  literature,  with  adequate
alidity  and  packaging,  as  well  as  correct  storage  rec-
mmendations,  quality  control  procedures  and  medication
raceability.
The  frequencies  of  requests  for  pediatric  compounded
ral  liquid  formulations  in  relation  to:  the  month
f  request;  their  active  principle;  their  Anatomical-
herapeutic-Chemical  (ATC)  classiﬁcation,5 and  requesting
ectors  were  calculated.
The  administration  frequency  of  magistral  oral  solutions
nd  suspensions  was  analyzed  for  total  oral  use  liquid  phar-
aceutical  forms  dispensed  by  the  hospital  pharmacy  to  the
eonatal  intensive  care  unit  and  Pediatrics  in  2013.
The  annual  consumption  of  infant  deﬁned  number  of  daily
ose  (iDDD),  which  corresponds  to  1/10  of  the  deﬁned  daily
ose  (DDD),  was  calculated  for  each  active  principle  of  these
reparations,  assuming  the  complete  consumption  of  the
ompounded  product.  The  number  of  iDDD/100  bed-days
as  also  calculated  for  patients  in  the  NICU.6 The  total  occu-
ation  of  beds  in  this  sector  was  considered  to  calculate  the
umber  of  beds  in  the  NICU.Descriptive  statistics  tools  such  as  mean,  standard  devia-
ion  and  frequency  distributions  were  used  for  data  analysis.
This  study  was  approved  by  the  Institutional  Review  Board
f  the  UFF  (n.  765.880  de  08/08/2014).
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Table  1  Use  of  non-licensed  manipulated  oral  liquid  preparations  for  newborns  and  children  at  a  hospital  in  2012  and  2013
(n=657).
Magistral  oral
solution/suspension
Frequency  of  requests
for  newborns  and
children  in  2012  and
2013
Established
oral  iDDD
(mg)
N.  of  iDDD
consumed  by
newborns  and
children  in  2012
N.  of  iDDD
consumed  by
newborns  and
children  in  2013
N.  of  iDDD/
100  bed-days
consumed  by  the
NICU  in  2012  and  2013
Folic  acid 11  0.04  12,625.0  3,900.0  146.1
Folinic acid 88  6  178.3 237.5  2.6
Ursodeoxycholic  acid 5  75  61.3 20.0 0.6
Amiodarone  1  20  48.0 0  0
Caffeine 53  40  212.5  226.3  4.0
Captopril 73  5  2842.0  1652.0  21.8
Sodium citrate  2 a b b b
Enalapril  6  1  420.0  660.0  0.0
Spironolactone  67  7.5  1132.8  788.0  9.7
Fluconazole 4  20  75.0  130.0  0
Furosemide 63  4  2558.8  1655.0  11.8
Hydralazine 1  10  7.5  0  0
Hydrochlorothiazide  43  2.5  1976.0  1848.0  33.3
Pyrazinamide  2  150  64.0  0  0
Pyridoxine 1  16  937.5  0  0
Pyrimethamine  63  7.5  528.7  338.0  4.9
Propranolol 4  16  10.3  0  0.1
Ranitidine 18  30  232.5  186.3  3.8
Sildenaﬁl 55  5  621.6  282.0  4.9
Sulfadiazine 85  60  2971.7  3041.7  36.5
Zinc sulfate 12  60  12.3 6.7  0.1
a Either DDD or iDDD was not identiﬁed for sodium citrate.
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Results
The  study  analyzed  657  compounding  request  forms  for  oral
liquid  preparations  intended  for  infants  and  children  in  the
NICU,  obstetrics  (rooming-in  newborns),  pediatrics  and  pedi-
atric  emergency  services.
Of  the  assessed  newborn  and  infant  services,  the  NICU
was  the  unit  with  the  highest  number  of  requests  (457;
69.6%),  followed  by  pediatrics  (99;  15.1%),  obstetrics  (71,
10,  8%);  pediatric  emergency  (27;  4.1%)  and  non-identiﬁed
sector  (3,  0.4%).
Per  month,  an  average  of  27  magistral  oral  solutions  and
suspensions  (standard  deviation=9.8)  were  requested.  The
months  with  the  highest  and  lowest  number  of  requests
were  in  March  2013  (45  requests)  and  December  2012  and
November  2013  (both  with  10  requests),  respectively.
The  most  often  requested  drug  classes  during  the  study
period,  according  to  the  ATC,  were:  C--cardiovascular  sys-
tem  (258  requests--especially  captopril,  spironolactone  and
furosemide);  J--anti-infective  for  systemic  use  (91  requests--
mainly  sulfadiazine)  and  V--varied  (88  requests--
corresponding  to  folinic  acid).  The  least  requested
class  was  B--blood  and  blood-forming  organs  (13  requests--
corresponding  to  folic  acid  and  sodium  citrate).In  2013,  318  liquid  pharmaceutical  forms  for  oral  use
were  dispensed  to  the  NICU  and  900  to  the  Pediatrics  unit,
of  which  209  (65.7%)  and  40  (4.4%)  were  compounded  oral
solutions  and  suspensions,  respectively.
h
t
o newborns and children and the number of iDDD/100 bed-days
e to lack of information on DDD or iDDD for sodium citrate.
The  frequencies  of  requests  for  pediatric  compounded
ral  solutions  and  suspensions  were  calculated  in  relation  to
he  active  principle  requested  for  these  preparations.  The
onsumption  of  active  principle  through  the  iDDD  number
f  these  medications  in  infants  and  children  was  also  cal-
ulated,  as  well  as  the  number  of  iDDD/100  bed-days  of
atients  in  the  NICU  (Table  1).
iscussion
he  need  for  the  use  of  magistral  preparations  to  cope  with
he  lack  of  oral  liquid  formulations  from  the  pharmaceuti-
al  industry  was  demonstrated  in  this  study,  which  identiﬁed
57  magistral  oral  solutions  and  suspensions,  regarding  21
ifferent  active  principles,  which  have  been  used  in  the
reatment  of  newborns  and  children  at  HUAP  in  2012  and
013.  It  is  noteworthy  that  the  main  characteristics  of
he  assessed  hospital  are:  being  a  public  hospital;  provid-
ng  middle-  and  high-complexity  care;  providing  specialized
utpatient  care,  urgency,  emergency  care  and  hospital
dmission  to  patients  from  the  Uniﬁed  Health  System;  in
ddition  to  teaching  (Graduation,  Post-Graduation,  medi-
al  and  multiprofessional  residency)  and  research  activities,
haracteristics  that  are  similar  to  other  Brazilian  university
ospitals.
Other  studies  also  demonstrated  the  need  for  these  solu-
ions  and  suspensions  for  pediatric  therapy.  Modiﬁcations
f  pharmaceutical  drug  forms  have  been  reported  by  Oguz
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t  al.  and  Khdour  et  al.,  who  identiﬁed,  respectively,  20.5%
nd  5.8%  modiﬁcations  in  requests.7,8 Costa  et  al.  found
19  drug  adaptations  from  solid  to  liquid  form  and  Gavrilov
t  al.  identiﬁed  two  dose  modiﬁcations  in  pharmaceutical
orms.9,10 Dos  Santos  and  Heineck  found  that  79  prescription
tems  involved  extemporaneous  preparations.11 Extempora-
eous  compounded  oral  preparations  are  magistral  drugs
hat  should  be  used  within  48hours.3
Important  regulatory  initiatives  were  developed  in
urope,  United  States  and  Australia  to  increase  the  num-
er  of  available  pediatric  drugs,  but  Brazil  still  lacks
peciﬁc  regulation  for  the  registration  and  use  of  pedi-
tric  drugs  and  an  incentive  policy  regarding  pediatric
esearch.9
Oral  solutions  and  suspensions  compounded  by  the  hos-
ital  pharmacy  or  prepared  through  the  modiﬁcation  of
he  pharmaceutical  form  performed  by  the  nursing  staff
re  often  studied  in  the  category  of  unlicensed  drug  use.
he  deﬁnition  of  unlicensed  drug  use  in  pediatrics  includes
hose  originated  from  licensed  drugs  modiﬁcations,  such  as
hose  that  underwent  pharmaceutical  form  modiﬁcation,
hose  without  authorization  to  be  sold  from  the  regulatory
gency,  imported  drugs,  the  contraindicated  drugs  and  those
hat  have  no  information  on  use  in  this  population--although
here  are  divergences  among  specialists.12,13
The  use  of  unlicensed  and  off-label  medications  (of  which
se  is  unauthorized  by  a  regulatory  agency)  in  pediatric
atients  have  been  the  subject  of  several  studies,  as  they  are
ften  prescribed  to  this  population,  particularly  newborns,
espite  the  high  frequency  of  adverse  reactions  associated
ith  their  use.13
Magalhães  et  al.  found  that  unlicensed  drug  use  in  hos-
italized  pediatric  patients  occurs  in  many  countries,  such
s  Brazil,  Sweden,  Croatia,  Turkey,  Estonia,  Netherlands,
alestine,  France,  Italy,  Germany,  Finland,  Switzerland,  Ser-
ia,  Spain,  Israel  and  England.13 In  Brazil,  there  are  few
tudies  on  the  use  of  magistral  drugs  in  infants  and  chil-
ren,  which  are  concentrated  in  hospitals  from  only  three
razilian  cities:  Fortaleza,9,14,15 Porto  Alegre11,16 and  Belo
orizonte.17,18
Observing  the  proﬁle  of  oral  solutions  and  suspensions
ompounded  for  newborns  and  children  of  the  stud-
ed  hospital,  it  was  veriﬁed  that  solutions/suspensions
f  these  active  principles  were  identiﬁed  in  other
tudies:  folic  acid,9,19 folinic  acid,9,20 ursodeoxycholic
cid,11,14 captopril,8,9,14,15,18,21 caffeine,12,16,19,22,23
pironolactone,9,24--28 ﬂuconazole,17 furosemide,8,9,26
ydrochlorothiazide,8,9,18,26,27 propranolol,10 ranitidine,9
yrimethamine17 and  sulfadiazine.17 Therefore,  it  is
bserved  that  the  demand  for  oral  solutions  and  suspen-
ions  administered  to  newborns  and  children  in  this  study
as  also  been  observed  in  other  studies  and  that  the  com-
ounding  of  drugs  is  a  national  and  international  necessity
ue  to  the  lack  of  oral  liquid  drugs  from  the  pharmaceutical
ndustry.
However,  it  is  important  to  note  that  some  medications
hat  require  compounding  to  be  obtained  in  oral  liquid
ormulation  in  a  certain  country  may  be  available  in  oth-
rs.  In  the  United  States,  for  instance,  the  following  drugs
re  approved  by  FDA  and  sold  as  oral  solution:  caffeine,
nalapril,  ﬂuconazole,  furosemide,  propranolol,  ranitidine,
nd  sildenaﬁl.29
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Regarding  the  recipients  of  the  magistral  oral  solutions
nd  suspensions,  it  was  observed  in  the  studied  hospital
hat  newborns  are  the  main  recipients  of  these  formulations
nd  that  the  NICU  is  responsible  for  70%  of  these  requests.
his  result  is  in  accordance  with  that  identiﬁed  by  Magal-
ães  et  al.,  which  indicate  that  most  unlicensed  drugs  are
rescribed  for  newborns  and  often  for  preterm  infants.13
The  comparison  of  results  on  medication  use  in  this  study
ith  those  of  other  studies  was  hindered  by  methodologi-
al  differences.  Other  authors  chose  to  analyze  magistral
rugs  as  cases  of  unlicensed  medication  use  and  expressed
esults  as  relative  frequency  (%)  of  unlicensed  items  in
rescriptions,  prescriptions  that  included  unlicensed  items
nd/or  patients  who  received  unlicensed  drugs.  The  present
tudy  concentrated  on  oral  solutions  and  suspensions  and
xpressed  its  results,  mainly  regarding  the  amount  of  active
rinciple  consumed  in  milligrams  per  number  of  iDDD  and
umber  of  iDDD/100  bed-days.  The  choice  of  showing  the
esults  of  this  study  in  relation  to  iDDD  was  based  on  the
ecommendation  made  by  the  WHO  on  the  use  of  DDD  in
rug  use  studies.
It should  be  observed  that  the  pharmaceutical  service
ivision,  responsible  for  adapting  active  ingredients  and/or
rugs  available  on  the  market  for  administration  in  hospital-
zed  patients,  is  scarce  in  Brazilian  hospitals,30 including  the
tudied  hospital.  Thus,  working  with  the  compounding  phar-
acy  is  very  important  to  allow  the  obtaining  of  magistral
rugs  necessary  for  the  treatment  of  newborns  and  children.
Costa  et  al.  reported  that  the  lack  of  the  drug  in
ppropriate  presentation  for  patient  administration  led  the
ursing  staff  to  make  dosage  form  changes  when  treat-
ng  patients.9,17 Of  the  pharmaceutical  form  adaptations,
5.63%  had  an  inappropriate  vehicle  and  there  were  also
ases  of  incorrect  packaging  and  conservation.9
Among  the  study  limitations  are  the  fact  that  a  single  hos-
ital  was  studied,  assuming  that  each  requested  preparation
as  consumed  in  full  and  that  the  NICU  occupancy  rate  was
00%  during  the  studied  period.  However,  it  is  noteworthy
hat  the  studied  hospital  proﬁle  is  similar  to  that  of  other
niversity  hospitals.  Additionally,  the  compounded  medica-
ion  was  prepared  for  a  speciﬁc  patient  and  had  a  small
olume  and  narrow  expiration  date,  making  it  reasonable  to
ssume  that  the  compounded  medication  was  consumed  in
ull.  Regarding  occupation,  the  studied  hospital  is  a  public
eference  health  unit,  which  provides  care  to  the  popula-
ion  of  a  densely  populated  area  and  the  occupancy  of  100%
f  beds  is  justiﬁable.  Thus,  the  generalization  of  the  results
ust  take  these  aspects  into  account.
It  is  noteworthy  that  the  use  of  magistral  drugs  may  be  a
ood  therapeutic  option  for  infants  and  children.  However,
egulatory  incentives  are  needed  for  the  pharmaceutical
ndustry  to  produce  these  drugs  at  adequate  dosage  for  this
opulation.
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